- Home
- BDRX vs PRPO Comparison
BDRX vs PRPO Comparison
Compare BDRX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- PRPO
- Stock Information
- Founded
- BDRX 2000
- PRPO N/A
- Country
- BDRX United Kingdom
- PRPO United States
- Employees
- BDRX N/A
- PRPO N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- BDRX Health Care
- PRPO Industrials
- Exchange
- BDRX Nasdaq
- PRPO Nasdaq
- Market Cap
- BDRX 5.8M
- PRPO 17.1M
- IPO Year
- BDRX N/A
- PRPO N/A
- Fundamental
- Price
- BDRX $0.84
- PRPO $14.51
- Analyst Decision
- BDRX
- PRPO
- Analyst Count
- BDRX 0
- PRPO 0
- Target Price
- BDRX N/A
- PRPO N/A
- AVG Volume (30 Days)
- BDRX 1.4M
- PRPO 20.0K
- Earning Date
- BDRX 04-11-2025
- PRPO 08-12-2025
- Dividend Yield
- BDRX N/A
- PRPO N/A
- EPS Growth
- BDRX N/A
- PRPO N/A
- EPS
- BDRX N/A
- PRPO N/A
- Revenue
- BDRX N/A
- PRPO $20,029,000.00
- Revenue This Year
- BDRX N/A
- PRPO N/A
- Revenue Next Year
- BDRX N/A
- PRPO N/A
- P/E Ratio
- BDRX N/A
- PRPO N/A
- Revenue Growth
- BDRX N/A
- PRPO 26.67
- 52 Week Low
- BDRX $0.78
- PRPO $3.90
- 52 Week High
- BDRX $24.75
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- BDRX 41.07
- PRPO 63.53
- Support Level
- BDRX $0.80
- PRPO $13.83
- Resistance Level
- BDRX $1.33
- PRPO $15.47
- Average True Range (ATR)
- BDRX 0.08
- PRPO 1.18
- MACD
- BDRX 0.01
- PRPO -0.01
- Stochastic Oscillator
- BDRX 10.38
- PRPO 62.16
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.